Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nivolumab/adverse effects"'
Autor:
Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jesper van Breeschoten, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk
Publikováno v:
European journal of cancer (Oxford, England : 1990), 167, 70-80. Elsevier Ltd.
van Not, O J, de Meza, M M, van den Eertwegh, A J M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, van Breeschoten, J, de Groot, J-W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Bonenkamp, H J, Boers-Sonderen, M J, Blokx, W A M, Wouters, M W J M & Suijkerbuijk, K P M 2022, ' Response to immune checkpoint inhibitors in acral melanoma : A nationwide cohort study ', European Journal of Cancer, vol. 167, pp. 70-80 . https://doi.org/10.1016/j.ejca.2022.02.026
European Journal of Cancer, 167, 70-80. ELSEVIER SCI LTD
European Journal of Cancer, 167, pp. 70-80
European Journal of Cancer, 167, 70-80
European Journal of Cancer, 167, 70-80. Pergamon
van Not, O J, de Meza, M M, van den Eertwegh, A J M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, van Breeschoten, J, de Groot, J-W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Bonenkamp, H J, Boers-Sonderen, M J, Blokx, W A M, Wouters, M W J M & Suijkerbuijk, K P M 2022, ' Response to immune checkpoint inhibitors in acral melanoma : A nationwide cohort study ', European Journal of Cancer, vol. 167, pp. 70-80 . https://doi.org/10.1016/j.ejca.2022.02.026
European Journal of Cancer, 167, 70-80. ELSEVIER SCI LTD
European Journal of Cancer, 167, pp. 70-80
European Journal of Cancer, 167, 70-80
European Journal of Cancer, 167, 70-80. Pergamon
Background: Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of immune checkpoint inhibitors in patients with stage III and IV AM and co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e0333d1ed14f8c5e0b759f512b98e9
http://www.scopus.com/inward/record.url?scp=85127559750&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85127559750&partnerID=8YFLogxK
Autor:
Sylvain Raoul Simeni Njonnou, Sandrine Aspeslagh, Marie-Josiane Ntsama Essomba, Marie-Lucie Racu, Fernando Kemta Lekpa, Frédéric Vandergheynst
Background Immune checkpoint inhibition with anti-PD(L)1 and anti-CTLA4 antibodies has significantly changed cancer treatment during the last 10 years. Nevertheless, boosting the immune system with immune checkpoint inhibition can result in immune-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc3c99386df1959c242a9a6cd2f3279
https://doi.org/10.1186/s13256-022-03663-6
https://doi.org/10.1186/s13256-022-03663-6
Autor:
Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid
Publikováno v:
Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063
Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ef4fae16505a538074156c51ab25a
https://doi.org/10.1158/1078-0432.ccr-20-2063
https://doi.org/10.1158/1078-0432.ccr-20-2063
Autor:
Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross-Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwenaëlle Gravis, Nadine Houede, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, Nicolas Doumerc, Philippe Paparel, Jean-Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, Géraldine Pignot, Elena Braychenko, Stefano Caruso, Cheng-Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougouïn, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard
Publikováno v:
Lancet Oncology
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩
International audience; Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a85c6d4558df8a8fb1a475ca37c2014
https://hal.science/hal-04072026
https://hal.science/hal-04072026
Autor:
Marco Zezza, Nelly Pitteloud, Haithem Chtioui, Laura Marino, Faiza Lamine, Carine Mekoguem, Christophe Kosinski
Publikováno v:
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144
BackgroundThe use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a722f98fa2436ff73199210f96e9153
https://doaj.org/article/5e85b5b762c841489b8519ccf9b5cc94
https://doaj.org/article/5e85b5b762c841489b8519ccf9b5cc94
Autor:
Monique C. Minnema, Margaret A. Shipp, Stephen M. Ansell, Nishitha Reddy, Scott J. Rodig, Jonathon B. Cohen, Selda Samakoglu, Kazunobu Kato, Margaretha G.M. Roemer, Sarit Assouline, Philippe Armand, Anne Sumbul, Michelle Poon, Peter Johnson, Azra H. Ligon, Manish Sharma, John M. Timmerman, Andrew Grigg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(6), 481. American Society of Clinical Oncology
Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bd249e2e8165cc0d45938a170ea405
https://doi.org/10.1200/jco.18.00766
https://doi.org/10.1200/jco.18.00766
Publikováno v:
Croatian Medical Journal
Volume 61
Issue 4
Volume 61
Issue 4
Aim To assess diseases outcomes and tolerability of real-life second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. ----- Methods This retrospective chart review involved prospectively monitored patients (named patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d807a701ee3b39fe7fd1be726737505
https://www.bib.irb.hr/1263395
https://www.bib.irb.hr/1263395
Publikováno v:
Annales de dermatologie et de vénéréologie, Vol. 147, No 3 (2020) pp. 221-227
Summary Background Cutaneous adverse effects of immunotherapies are being seen with increasing frequency in general practice. While anti-PD1 lichenoid reactions are well known, only a few cases of bullous lichen planus have so far been reported in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76966533d071408e7a6b05818262e81f
https://archive-ouverte.unige.ch/unige:147009
https://archive-ouverte.unige.ch/unige:147009
Autor:
Annabel Meireson, Piet Ost, Teofila Seremet, Jo Van Dorpe, Liesbeth Ferdinande, Nora Sundahl, Bart Neyns, Lieve Brochez, Vibeke Kruse
Purpose Nivolumab improves survival in patients with metastatic melanoma. Unfortunately, most patients do not respond to this treatment. Preclinical data indicate that radiation therapy could work synergistically with nivolumab and improve response r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f6019cfc276207deb92a753bddb0b2
https://biblio.vub.ac.be/vubir/phase-2-trial-of-nivolumab-combined-with-stereotactic-body-radiation-therapy-in-patients-with-metastatic-or-locally-advanced-inoperable-melanoma(707a28c4-923a-46bd-96f3-69c0fb0f2a41).html
https://biblio.vub.ac.be/vubir/phase-2-trial-of-nivolumab-combined-with-stereotactic-body-radiation-therapy-in-patients-with-metastatic-or-locally-advanced-inoperable-melanoma(707a28c4-923a-46bd-96f3-69c0fb0f2a41).html
Autor:
Vincent Pillonel, Olivier Michielin, Andreas F. Hottinger, Luis Schiappacasse, Veronica Aedo-Lopez, Gregoire Berthod, Vincent Dunet, Solange Peters
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Background Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events, including rare but severe ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405a051ce719beb9bfa688acb52fdc90
https://pubmed.ncbi.nlm.nih.gov/31791418
https://pubmed.ncbi.nlm.nih.gov/31791418